Cargando…
Copeptin as a marker of an altered CRH axis in pituitary disease
BACKGROUND: Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin closely reflects vasopressin release. Copeptin has been shown to subtly mirror stress potentially mediated via corticotrophin-releasing hormone. To further test a potential direct interaction of corticotrophin-releasing...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573756/ https://www.ncbi.nlm.nih.gov/pubmed/28795329 http://dx.doi.org/10.1007/s12020-017-1366-6 |
_version_ | 1783259704018862080 |
---|---|
author | Lewandowski, Krzysztof C. Lewiński, Andrzej Skowrońska-Jóźwiak, Elżbieta Malicka, Katarzyna Horzelski, Wojciech Brabant, Georg |
author_facet | Lewandowski, Krzysztof C. Lewiński, Andrzej Skowrońska-Jóźwiak, Elżbieta Malicka, Katarzyna Horzelski, Wojciech Brabant, Georg |
author_sort | Lewandowski, Krzysztof C. |
collection | PubMed |
description | BACKGROUND: Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin closely reflects vasopressin release. Copeptin has been shown to subtly mirror stress potentially mediated via corticotrophin-releasing hormone. To further test a potential direct interaction of corticotrophin-releasing hormone with copeptin release, which could augment vasopressin effects on pituitary function, we investigated copeptin response to corticotrophin-releasing hormone. PATIENTS AND METHODS: Cortisol, adrenocorticotropin and copeptin were measured in 18 healthy controls and 29 subjects with a history of pituitary disease during standard corticotrophin-releasing hormone test. RESULTS: Patients with previous pituitary disease were subdivided in a group passing the test (P1, n = 20) and failing (P2, n = 9). The overall copeptin response was higher in controls than in subjects with pituitary disease (area under the curve, p = 0.04 for P1 + P2) with a maximum increase in controls from 3.84 ± 2.86 to 12.65 ± 24.87 pmol/L at 30 min, p < 0.05. In contrast, both groups of pituitary patients lacked a significant copeptin response to corticotrophin-releasing hormone, and even in P1, where adrenocorticotropin concentrations increased fourfold (mean, 21.48 vs. 91.53 pg/mL, p < 0.01), copeptin did not respond (e.g., 4.35 ± 5.81 vs. 5.36 ± 6.79 pmol/L, at 30 min, p = ns). CONCLUSIONS: Corticotrophin-releasing hormone is able to stimulate copeptin release in healthy controls suggesting a direct interaction of corticotrophin-releasing hormone and vasopressin/vasopressin. Interestingly, this relation is altered already in the group of pituitary patients who pass the standard corticotrophin-releasing hormone test indicating (1) the corticotrophin-releasing hormone–adrenocorticotropin–cortisol response is largely independent from the vasopressin system, but (2) the corticotrophin-releasing hormone–vasopressin interaction reflected by copeptin may be much more sensitive to reveal subtle alterations in the regulation of pituitary function. |
format | Online Article Text |
id | pubmed-5573756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-55737562017-09-12 Copeptin as a marker of an altered CRH axis in pituitary disease Lewandowski, Krzysztof C. Lewiński, Andrzej Skowrońska-Jóźwiak, Elżbieta Malicka, Katarzyna Horzelski, Wojciech Brabant, Georg Endocrine Original Article BACKGROUND: Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin closely reflects vasopressin release. Copeptin has been shown to subtly mirror stress potentially mediated via corticotrophin-releasing hormone. To further test a potential direct interaction of corticotrophin-releasing hormone with copeptin release, which could augment vasopressin effects on pituitary function, we investigated copeptin response to corticotrophin-releasing hormone. PATIENTS AND METHODS: Cortisol, adrenocorticotropin and copeptin were measured in 18 healthy controls and 29 subjects with a history of pituitary disease during standard corticotrophin-releasing hormone test. RESULTS: Patients with previous pituitary disease were subdivided in a group passing the test (P1, n = 20) and failing (P2, n = 9). The overall copeptin response was higher in controls than in subjects with pituitary disease (area under the curve, p = 0.04 for P1 + P2) with a maximum increase in controls from 3.84 ± 2.86 to 12.65 ± 24.87 pmol/L at 30 min, p < 0.05. In contrast, both groups of pituitary patients lacked a significant copeptin response to corticotrophin-releasing hormone, and even in P1, where adrenocorticotropin concentrations increased fourfold (mean, 21.48 vs. 91.53 pg/mL, p < 0.01), copeptin did not respond (e.g., 4.35 ± 5.81 vs. 5.36 ± 6.79 pmol/L, at 30 min, p = ns). CONCLUSIONS: Corticotrophin-releasing hormone is able to stimulate copeptin release in healthy controls suggesting a direct interaction of corticotrophin-releasing hormone and vasopressin/vasopressin. Interestingly, this relation is altered already in the group of pituitary patients who pass the standard corticotrophin-releasing hormone test indicating (1) the corticotrophin-releasing hormone–adrenocorticotropin–cortisol response is largely independent from the vasopressin system, but (2) the corticotrophin-releasing hormone–vasopressin interaction reflected by copeptin may be much more sensitive to reveal subtle alterations in the regulation of pituitary function. Springer US 2017-08-09 2017 /pmc/articles/PMC5573756/ /pubmed/28795329 http://dx.doi.org/10.1007/s12020-017-1366-6 Text en © The Author(s) 2017 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Lewandowski, Krzysztof C. Lewiński, Andrzej Skowrońska-Jóźwiak, Elżbieta Malicka, Katarzyna Horzelski, Wojciech Brabant, Georg Copeptin as a marker of an altered CRH axis in pituitary disease |
title | Copeptin as a marker of an altered CRH axis in pituitary disease |
title_full | Copeptin as a marker of an altered CRH axis in pituitary disease |
title_fullStr | Copeptin as a marker of an altered CRH axis in pituitary disease |
title_full_unstemmed | Copeptin as a marker of an altered CRH axis in pituitary disease |
title_short | Copeptin as a marker of an altered CRH axis in pituitary disease |
title_sort | copeptin as a marker of an altered crh axis in pituitary disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573756/ https://www.ncbi.nlm.nih.gov/pubmed/28795329 http://dx.doi.org/10.1007/s12020-017-1366-6 |
work_keys_str_mv | AT lewandowskikrzysztofc copeptinasamarkerofanalteredcrhaxisinpituitarydisease AT lewinskiandrzej copeptinasamarkerofanalteredcrhaxisinpituitarydisease AT skowronskajozwiakelzbieta copeptinasamarkerofanalteredcrhaxisinpituitarydisease AT malickakatarzyna copeptinasamarkerofanalteredcrhaxisinpituitarydisease AT horzelskiwojciech copeptinasamarkerofanalteredcrhaxisinpituitarydisease AT brabantgeorg copeptinasamarkerofanalteredcrhaxisinpituitarydisease |